OBJECTIVES: Endoplasmic reticulum stress and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) by protein kinase R-like endoplasmic reticulum kinase (PERK) plays an important role in the development and chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the expression and significance of phosphorylated eIF2α (p-eIF2α) and PERK in PDAC have not been examined. METHODS: We examined p-eIF2α and PERK expression in 84 PDAC and paired normal pancreas samples by immunohistochemistry and Western blotting and correlated the results with clinicopathologic parameters and survival. RESULTS: Mean PERK H score was 140.8 in PDAC compared with 82.1 in normal pancreas (P < 0.001). High p-eIF2α expression was present in 56% of PDACs versus 7.6% of normal pancreases (P < 0.001). High PERK and p-eIF2α expression correlated with shorter overall survival (P = 0.048 and P = 0.03, respectively). By multivariate analysis, high p-eIF2α (P = 0.01), positive margin (P = 0.002), and lymph node metastasis (P = 0.01) were independent prognosticators for survival. CONCLUSIONS: The expression levels of PERK and p-eIF2α are higher in PDAC than those in normal pancreas. High levels of PERK and p-eIF2α are predictors of shorter survival in PDAC patients, suggesting that PERK and eIF2α could be promising targets in PDAC.
OBJECTIVES: Endoplasmic reticulum stress and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) by protein kinase R-like endoplasmic reticulum kinase (PERK) plays an important role in the development and chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the expression and significance of phosphorylated eIF2α (p-eIF2α) and PERK in PDAC have not been examined. METHODS: We examined p-eIF2α and PERK expression in 84 PDAC and paired normal pancreas samples by immunohistochemistry and Western blotting and correlated the results with clinicopathologic parameters and survival. RESULTS: Mean PERK H score was 140.8 in PDAC compared with 82.1 in normal pancreas (P < 0.001). High p-eIF2α expression was present in 56% of PDACs versus 7.6% of normal pancreases (P < 0.001). High PERK and p-eIF2α expression correlated with shorter overall survival (P = 0.048 and P = 0.03, respectively). By multivariate analysis, high p-eIF2α (P = 0.01), positive margin (P = 0.002), and lymph node metastasis (P = 0.01) were independent prognosticators for survival. CONCLUSIONS: The expression levels of PERK and p-eIF2α are higher in PDAC than those in normal pancreas. High levels of PERK and p-eIF2α are predictors of shorter survival in PDACpatients, suggesting that PERK and eIF2α could be promising targets in PDAC.
Authors: Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson Journal: Clin Cancer Res Date: 2012-08-15 Impact factor: 12.531
Authors: Aparna C Ranganathan; Shishir Ojha; Antonis Kourtidis; Douglas S Conklin; Julio A Aguirre-Ghiso Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Kasper M Rouschop; Ludwig J Dubois; Tom G Keulers; Twan van den Beucken; Philippe Lambin; Johan Bussink; Albert J van der Kogel; Marianne Koritzinsky; Bradly G Wouters Journal: Proc Natl Acad Sci U S A Date: 2013-03-07 Impact factor: 11.205
Authors: Charity Atkins; Qi Liu; Elisabeth Minthorn; Shu-Yun Zhang; David J Figueroa; Katherine Moss; Thomas B Stanley; Brent Sanders; Aaron Goetz; Nathan Gaul; Anthony E Choudhry; Hasan Alsaid; Beat M Jucker; Jeffrey M Axten; Rakesh Kumar Journal: Cancer Res Date: 2013-01-18 Impact factor: 12.701
Authors: Yong He; Arlene M Correa; Maria Gabriela Raso; Wayne L Hofstetter; Bingliang Fang; Carmen Behrens; Jack A Roth; Yihong Zhou; Liping Yu; Ignacio I Wistuba; Stephen G Swisher; Apar Pataer Journal: PLoS One Date: 2011-11-10 Impact factor: 3.240